Analysis Clinical Effect of Femoston with Esomeprazole Treatment on GERD in Perimenopausal Women

doi:10.3877/cma.j.issn.2095-8765.2021.03.003

Abstract

Abstract:

Objective

To analyze the clinical aspects of perimenopausal women with gastroesophageal reflux disease (GERD) andthe clinical effects of femoston combined with esomeprazole in the treatment of perimenopausal women with GERD.

Methods

A retrospective study made on 80 patients whom with perimenopausal GERD between March 2020 to March 2021 in our hospital were analyzed. According to different treatment methods, all patients was grouped as control (n=40) and observation(n=40); the control group was treated with esomeprazole; the observation group was given femoston that on the basis of esomeprazole, and the two groups were treated for 6 months. Kupperman questionnaire, GERD questionnaire, 24-h pH monitoring of gastric acid, high-resolution esophageal motilityand sex hormones wereused to analyze the clinical effects of that combination therapy.

Results

The perimenopausal symptom score and GERD score of theobservation groups were markedly decline than pre treatment(P＜0.05); compared with before treatment, the levels of proximal esophageal weak acid reflux(%), proximal esophageal acid reflux(%) and Demeester score decreased significantly after treatment (P＜0.05); the resting pressure of lower esophageal sphincter (LES) and DCI increased significantly after treatment compared with those before treatment (P＜0.05); the levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH) were significantly decrease in the observation group after treatment (P＜0.05); at the same time, the level of estradiol (E2) was significantly increased (P＜0.05); the clinical efficacy of the observation group was excellent than that of the control group (P＜0.05); the ineffective rate of the observation group was markedly lower (P＜0.05); the incidence of adverse drug reactions such as headache, nausea, vomiting and breast pain in the observation group was significantly lower than that in the control group (P＜0.05).

Conclusion

The combined therapy has a good effect on perimenopausal with GERD, and can significantly improve the occurrence of perimenopausal and GERD symptoms, that is considerable for further clinical application.

Key words: gastroesophageal reflux disease, perimenopausal, symptom, esomeprazole, femoston

Amina·Shawuti, Aziguli·Alimujiang, Maimaiti·Yisireyili, Jing Wang, Ababokeli·Wusiman, Meihua Chen, Ping Lu, Kelimu·Abudureyimu. Analysis Clinical Effect of Femoston with Esomeprazole Treatment on GERD in Perimenopausal Women[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2021, 08(03): 123-128.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwsgflbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8765.2021.03.003

https://zhwsgflbdzzz.cma-cmc.com.cn/EN/Y2021/V08/I03/123

Figures/Tables 7

References 18

1	Willi J, Ehlert U. Assessment of perimenopausal depression: A review [J]. J Affect Disord, 2019, 15; 249:216-222.
2	Savarino V, Marabotto E, Zentilin P, et al. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease [J]. Expert Rev Clin Pharmacol, 2020, 13(4):437-449.
3	Royston C, Bardhan KD. Adam, Eve and the reflux enigma: age and sex differences across the gastro-oesophageal reflux spectrum [J]. Eur J Gastroenterol Hepatol, 2017, 29(6):634-639.
4	中国医师协会外科医师分会胃食管反流病专业委员会. 胃食管反流病外科诊疗共识(2019版) [J]. 中华胃食管反流病电子杂志, 2019, 6(1):3-9.
5	黄志英,丁岩. 围绝经期女性代谢综合征的相关研究进展 [J]. 国际妇产科学杂志, 2020, 47(1):84-87.
6	周燕. 卵巢功能衰退阶段绝经相关症状影响因素研究 [J]. 现代职业教育, 2020, 5(1):226-227.
7	陈萍, 李霞, 杨朝霞. 围绝经期女性胃食管反流病的临床特征分析 [J]. 重庆医学, 2017, 34(3):289-291.
8	阿孜古丽·阿力木江, 赵新胜, 王婧, 等. 妊娠期胃食管反流病的症状特征研究 [J]. 中华胃食管反流病电子杂志, 2019, 3(6): 139-143.
9	Torihata Y, Asanuma K, Iijima K, et al. Estrogen-Dependent Nrf2 Expression Protects Against Reflux-Induced Esophagitis [J]. Dig Dis Sci, 2018, 63(2):345-355.
10	Tsai CC, Tey SL, Chang LC, et al. Estradiol mediates relaxation of porcine lower esophageal sphincter [J]. Steroids, 2018, 136:56-62.
11	MacGregor EA. Migraine, menopause and hormone replacement therapy [J]. Post Reprod Health, 2018, 24(1):11-18.
12	郭蜜甜. 坤泰胶囊联合雌二醇片雌二醇地屈孕酮片复合包装序贯疗法治疗围绝经期综合征效果观察 [J]. 中国民康医学, 2019, 31(6):101-103.
13	胃食管反流病基层诊疗指南(2019年) [J]. 中华全科医师杂志, 2019, 18(7):635-641.
14	Chang HC, Chang YS, Wang KH, et al. Esomeprazole-induced ashy dermatosis-like drug eruptions [J]. Australas J Dermatol, 2019, 60(3):e232-e233.
15	邹孟龙,宁芯,陈雅璐,等. 胃食管反流病患者酸反流与食管动力的相关性研究 [J]. 海南医学院学报, 2020, 68(21):41-45.
16	尚琪, 郭丽芳, 张翠霞, 等. 质子泵抑制剂临床应用新领域 [J]. 胃肠病学, 2017(22):699.
17	Scarpignato C, Hongo M, Wu JCY, et al. Pharmacologic treatment of GERD: Where we are now, and where are we going? [J]. Ann N Y Acad Sci, 2020, 1482(1):193-212.
18	中国药学会. 质子泵抑制剂优化应用专家共识 [J]. 中国医院药学杂志, 2020, 40(21):7-25.

组别	例数	年龄（岁）	身体质量指数（kg/m²）	病程（年）
对照组	40	50.27±6.65	25.78±2.45	2.05±0.45
观察组	40	51.36±5.20	24.45±1.78	1.90±0.60
t		1.020	0.875	0.775
p		＞0.05	＞0.05	＞0.05

组别	例数	年龄（岁）	身体质量指数（kg/m²）	病程（年）
对照组	40	50.27±6.65	25.78±2.45	2.05±0.45
观察组	40	51.36±5.20	24.45±1.78	1.90±0.60
t		1.020	0.875	0.775
p		＞0.05	＞0.05	＞0.05

组别	例数	Kupperman评分		GERD评分
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	40	28.15±5.78	16.25±3.62^a	20.40±2.70	12.65±1.27^a
观察组	40	30.23±4.15	9.50±2.85^bc	20.91±1.85	7.84±1.12^bc
t		0.672	-1.985	0.784	-2.415
p		＞0.05	＜0.05	＞0.05	＜0.05

组别	例数	Kupperman评分		GERD评分
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	40	28.15±5.78	16.25±3.62^a	20.40±2.70	12.65±1.27^a
观察组	40	30.23±4.15	9.50±2.85^bc	20.91±1.85	7.84±1.12^bc
t		0.672	-1.985	0.784	-2.415
p		＞0.05	＜0.05	＞0.05	＜0.05

组别	例数	食管近端弱酸反流（%）		食管近端酸反流（%）		DeMeester评分（分）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	40	70.30±8.75	48.60±6.12^a	83.74±7.62	65.12±5.58^a	35.45±5.68	16.10±4.22^a
观察组	40	72.65±10.40	40.15±8.24^b	85.36±5.74	52.76±7.35^b	38.15±4.76	13.17±2.21^b
t		1.020	2.215	0.967	2.012	0.895	1.913
P		0.112	0.018	0.183	0.025	0.415	0.041

Please choose a citation manager

Content to export